Mabwell(SH:688062) 智通财经网·2025-08-31 08:33Core Viewpoint - Maiwei Biotech (688062.SH) has received the acceptance notice from the National Medical Products Administration (NMPA) for the Phase II clinical trial application of 9MW3811 injection for pathological scar indications [1] Company Summary - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, developed independently by Maiwei Biotech, classified as a Class 1 therapeutic biological product with independent intellectual property rights [1] - The mechanism of 9MW3811 involves high-affinity binding to IL-11, effectively inhibiting the abnormal activation of the IL-11/IL-11Rα signaling pathway, thereby intervening in the pathological progression of fibrotic diseases [1] - Key advantages of 9MW3811 include higher target affinity and signaling blockade capability, as well as a half-life exceeding one month, making it suitable for the treatment of chronic diseases requiring long-term administration [1]